BioXcel Therapeutics, Inc. (BTAI)
Company Description
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.
In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.
BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Country | United States |
Founded | 2017 |
IPO Date | Mar 8, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 74 |
CEO | Dr. Vimal D. Mehta Ph.D. |
Contact Details
Address: 555 Long Wharf Drive New Haven, Connecticut 06511 United States | |
Phone | 203-643-8060 |
Website | bioxceltherapeutics.com |
Stock Details
Ticker Symbol | BTAI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001720893 |
CUSIP Number | 09075P105 |
ISIN Number | US09075P1057 |
Employer ID | 82-1386754 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Vimal D. Mehta Ph.D. | Founder, Chief Executive Officer, President, and Director |
Javier Rodriguez | Senior Vice President, Chief Legal Officer and Corporate Secretary |
Matthew Wiley | Senior Vice President and Chief Commercial Officer |
Richard I. Steinhart MBA | Senior Vice President and Chief Financial Officer |
Dr. Frank D. Yocca Ph.D. | Senior Vice President and Chief Scientific Officer |
Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P. | Executive Vice President and Chief of Product Development and Medical Officer |
Dr. Chetan D. Lathia Ph.D. | Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs |
Dr. Robert Risinger M.D. | Chief Medical Officer - Neuroscience |
Robert Scala | Vice President of Commercial Operations and Launch Planning |
Dr. Friso Postma | Senior Director of Neuroscience and Artificial intelligence |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2024 | 8-K | Current Report |
Mar 25, 2024 | 424B5 | Filing |
Mar 22, 2024 | 10-K | Annual Report |
Mar 12, 2024 | 8-K | Current Report |
Feb 14, 2024 | 8-K | Current Report |
Feb 12, 2024 | 8-K | Current Report |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 8, 2024 | 424B5 | Filing |
Feb 8, 2024 | 8-K | Current Report |
Feb 8, 2024 | 8-K | Current Report |